Diamyd Medical contributes to JDRF initiative to increase understanding of type 1 diabetes
Diamyd Medical (Nasdaq Stockholm First North, Ticker: DMYD B) announced today that the Company has joined a research initiative aimed at increasing the understanding of the natural progression of type 1 diabetes in order to transform and accelerate drug development for the disease. Diamyd Medical will contribute data from the control (placebo) arm of its European Phase III study with the diabetes vaccine Diamyd®. The data will be made available to the research community in an open access database together with similar data from other late stage studies in type 1 diabetes.“Diamyd Medical’s